Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia / Schizoaffective Disorder Clear all
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 15, 2026, 6:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Perceptual Deficits in Schizophrenia

NCT02337439
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sensory Information Processing Training, Active Control Training
Behavioral
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers

NCT02386605
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivational Interviewing and Cognitive Behavioral Therapy, Relaxation Skills
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

NCT00337662
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Little Rock, Arkansas • Escondido, California • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

NCT00709202
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Betahistine, Placebo Oral Tablet
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

NCT00306475
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Divalproex Sodium Extended-Release Tablets, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 6:54 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 15, 2026, 6:54 AM EDT
Recruiting Phase 4 Interventional

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Clozapine, treatment as usual
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

D-serine Augmentation of Neuroplasticity

NCT03711500
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 2 Interventional Results available

Transcranial Magnetic Stimulation for "Voices"

NCT00308997
View directory record Official record
Conditions
Schizophrenia, Hallucinations
Interventions
1-hertz Repetitive Transcranial Magnetic Stimulation, Active 1-Hertz Repetitive transcranial magnetic stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCT05779241
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LYN-005, Risperidone
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Horyzons: Implementation in Clinical Practice

NCT04673851
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
Horyzons USA
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
PACE-Life, Exercise Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People

NCT00169052
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
Health Care Management and Supported Rehabilitation
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older · Female only
Enrollment
180 participants
Timeline
2001 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts • Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers

NCT00392236
View directory record Official record
Conditions
Schizophrenia
Interventions
2-way pager, Treatment as usual
Device · Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 15, 2026, 6:54 AM EDT
Active, not recruiting Not applicable Interventional

Optimizing CBSST With Executive Function Training for Schizophrenia

NCT06251193
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
E-CBSST
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Clinical Trial of AVL-3288 in Schizophrenia Patients

NCT02978599
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
AVL-3288, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

NCT00634348
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Ziprasidone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Culver City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 15, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Sodium Nitroprusside in Early Course Schizophrenia

NCT04986072
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Sodium Nitroprusside, 5% Dextrose solution
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 15, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 15, 2026, 6:54 AM EDT